1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of Daily Coffee Consumption on the Risk of Alzheimer’s Disease: A Systematic Review and Meta-Analysis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer’s disease (AD) is a highly prevalent neurodegenerative disorder that affects millions of individuals globally. The identification of the lifestyle factors that potentially help prevent or postpone disease onset is of interest to the researchers. Although the study results are inconsistent, one such factor that has been extensively studied is coffee consumption. Therefore, this meta-analysis primarily aimed to investigate the effects of coffee consumption on the risk of AD. Pubmed, Embase, and Web of Science (Only Writing Web of Science is Fine) databases were searched for relevant studies with the keywords in various combinations, including “coffee”, “caffeine”, and “Alzheimer’s disease”. This meta-analysis included 11 studies. The relative risk (RR) with 95% confidence intervals (CI) was calculated to estimate the effect size. The study used the restricted maximum-likelihood method for a generic-inverse-variance analysis with random-effect (when heterogeneity, I 2 > 50%) or fixed-effect (when heterogeneity, I 2 < 50%) modeling. The study protocol has been registered at International Prospective Register of Systematic Reviews (CRD42023429016). Individuals that regularly consumed 1-2 cups and 2-4 cups coffee/day demonstrated a significantly lower risk of developing AD (1-2 cups/day: RR = 0.68, 95% CI = 0.54 to 0.83, I 2 = 50.99%, p = 0.00 [the software used for analysis, shows the results of p value like this (0.00), I prefer not to change this as this is also fine]; 2-4 cups/day: RR = 0.79, 95% CI = 0.56 to 1.02, I 2 = 71.79%, p = 0.00). However, individuals who consumed > 4 cups/day demonstrated an increased risk of developing AD (RR = 1.04, 95% CI = 0.91 to 1.17, I 2 = 0.00%, p = 0.00). This meta-analysis indicates that limited (1-4 cups/day) daily coffee consumption reduces the risk of AD, whereas excessive consumption (> 4 cups/day) might increase the risk.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

          J. Lindsay (2002)
          A prospective analysis of risk factors for Alzheimer's disease was a major objective of the Canadian Study of Health and Aging, a nationwide, population-based study. Of 6,434 eligible subjects aged 65 years or older in 1991, 4,615 were alive in 1996 and participated in the follow-up study. All participants were cognitively normal in 1991 when they completed a risk factor questionnaire. Their cognitive status was reassessed 5 years later by using a similar two-phase procedure, including a screening interview, followed by a clinical examination when indicated. The analysis included 194 Alzheimer's disease cases and 3,894 cognitively normal controls. Increasing age, fewer years of education, and the apolipoprotein E epsilon4 allele were significantly associated with increased risk of Alzheimer's disease. Use of nonsteroidal anti-inflammatory drugs, wine consumption, coffee consumption, and regular physical activity were associated with a reduced risk of Alzheimer's disease. No statistically significant association was found for family history of dementia, sex, history of depression, estrogen replacement therapy, head trauma, antiperspirant or antacid use, smoking, high blood pressure, heart disease, or stroke. The protective associations warrant further study. In particular, regular physical activity could be an important component of a preventive strategy against Alzheimer's disease and many other conditions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review

            Background The PRISMA Statement is a reporting guideline designed to improve transparency of systematic reviews (SRs) and meta-analyses. Seven extensions to the PRISMA Statement have been published to address the reporting of different types or aspects of SRs, and another eight are in development. We performed a scoping review to map the research that has been conducted to evaluate the uptake and impact of the PRISMA Statement and extensions. We also synthesised studies evaluating how well SRs published after the PRISMA Statement was disseminated adhere to its recommendations. Methods We searched for meta-research studies indexed in MEDLINE® from inception to 31 July 2017, which investigated some component of the PRISMA Statement or extensions (e.g. SR adherence to PRISMA, journal endorsement of PRISMA). One author screened all records and classified the types of evidence available in the studies. We pooled data on SR adherence to individual PRISMA items across all SRs in the included studies and across SRs published after 2009 (the year PRISMA was disseminated). Results We included 100 meta-research studies. The most common type of evidence available was data on SR adherence to the PRISMA Statement, which has been evaluated in 57 studies that have assessed 6487 SRs. The pooled results of these studies suggest that reporting of many items in the PRISMA Statement is suboptimal, even in the 2382 SRs published after 2009 (where nine items were adhered to by fewer than 67% of SRs). Few meta-research studies have evaluated the adherence of SRs to the PRISMA extensions or strategies to increase adherence to the PRISMA Statement and extensions. Conclusions Many studies have evaluated how well SRs adhere to the PRISMA Statement, and the pooled result of these suggest that reporting of many items is suboptimal. An update of the PRISMA Statement, along with a toolkit of strategies to help journals endorse and implement the updated guideline, may improve the transparency of SRs. Electronic supplementary material The online version of this article (10.1186/s13643-017-0663-8) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study.

              Caffeine stimulates central nervous system on a short term. However, the long-term impact of caffeine on cognition remains unclear. We aimed to study the association between coffee and/or tea consumption at midlife and dementia/Alzheimer's disease (AD) risk in late-life. Participants of the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study were randomly selected from the survivors of a population-based cohorts previously surveyed within the North Karelia Project and the FINMONICA study in 1972, 1977, 1982 or 1987 (midlife visit). After an average follow-up of 21 years, 1409 individuals (71%) aged 65 to 79 completed the re-examination in 1998. A total of 61 cases were identified as demented (48 with AD). Coffee drinkers at midlife had lower risk of dementia and AD later in life compared with those drinking no or only little coffee adjusted for demographic, lifestyle and vascular factors, apolipoprotein E epsilon4 allele and depressive symptoms. The lowest risk (65% decreased) was found in people who drank 3-5 cups per day. Tea drinking was relatively uncommon and was not associated with dementia/AD. Coffee drinking at midlife is associated with a decreased risk of dementia/AD later in life. This finding might open possibilities for prevention of dementia/AD.
                Bookmark

                Author and article information

                Journal
                J Lifestyle Med
                J Lifestyle Med
                Journal of Lifestyle Medicine
                Yonsei University Wonju College of Medicine
                2234-8549
                2288-1557
                31 August 2023
                31 August 2023
                31 August 2023
                : 13
                : 2
                : 83-89
                Affiliations
                [1 ]Institute of Digital Anti-aging Healthcare, Graduate School of Inje University, Gimhae, Republic of Korea
                [2 ]Biohealth Products Research Center, Inje University, Gimhae, Republic of Korea
                [3 ]Research Center for Aged-life Redesign, Inje University, Gimhae, Republic of Korea
                [4 ]Department of Physical Therapy, Graduate School of Inje University, Gimhae, Republic of Korea
                [5 ]Department of Physical Therapy, College of Healthcare Medical Science & Engineering, Inje University, Gimhae, Republic of Korea
                [6 ]Department of Rehabilitation Science, Graduate School of Inje University, Gimhae, Republic of Korea
                Author notes
                [* ] Corresponding author: Yonggeun Hong Department of Rehabilitation Science, Graduate School of Inje University, 197 Inje-ro, Gimhae, Gyeongsangnam-do 50834, Republic of Korea Tel: +82-55-320-3681 E-mail: yonghong@ 123456inje.ac.kr
                Author information
                https://orcid.org/0000-0003-2792-2139
                https://orcid.org/0000-0003-0680-757X
                https://orcid.org/0000-0002-0737-0253
                https://orcid.org/0000-0003-1288-0546
                Article
                jlm-13-2-83
                10.15280/jlm.2023.13.2.83
                10630722
                37970326
                da7dc6ab-0ece-4f67-9cac-58aa211ce1e0
                © 2023 Journal of Lifestyle Medicine

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 30 May 2023
                : 8 June 2023
                : 26 July 2023
                Categories
                Review Article

                alzheimer disease,caffeine,coffee,meta-analysis,risk,systematic review

                Comments

                Comment on this article